Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  The Blackstone Group Inc.    BX

THE BLACKSTONE GROUP INC.

(BX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Blackstone : Precision Medicine Group Secures Major Investment from Blackstone

11/20/2020 | 09:03am EST

Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, Ethan Leder and Mark Clein, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT, and Vida Ventures.

Bethesda, Maryland-based PMG is a leading provider of mission-critical services to help biopharmaceutical companies conduct clinical trials and bring novel therapies to market by integrating deep therapeutic knowledge, data and analytics, and human expertise. With precision medicine as its foundation, PMG’s specialized capabilities enable the development and delivery of more targeted treatments for patients, addressing the next wave of innovation in global health advancement, expanded access, and outcomes improvement.

This new round of investment will fuel the expansion of PMG’s global footprint and technical capabilities to help accelerate the development, approval, and commercial reach of breakthrough treatments from life science innovators. Blackstone’s deep understanding of the drug development process and extensive operating resources will help deliver significant value to the partnership.

Mark Clein, PMG CEO, said: “We are thrilled to have Blackstone join us for this next phase of growth. Their serious commitment to the life sciences and global scope and scale make them an ideal partner to support our vision of success and expanded capabilities for the next generation of bio-pharma innovators.”

Julia Kahr, a Senior Managing Director at Blackstone, said: “PMG has built a compelling set of services that address the most important challenges facing biopharmaceutical and diagnostic companies. We are eager to back Mark and Ethan and the highly talented employees around the world to support their deep and ongoing commitment to PMG’s clients and look forward to pursuing the immense opportunity ahead by leveraging new technologies, expertise, and scale. We are also delighted to be joining Berkshire, TPG Growth, Oak HC/FT, and Vida to help accelerate this success.”

Anushka Sunder, Managing Director at Blackstone, added: “We have high conviction in the unprecedented wave of innovation PMG’s clients are driving in personalized medicines and novel drug mechanisms, especially in oncology and rare disease. PMG integrates deep science, extensive biomarker and genetic data, evidence of economic value, and market access insights to improve the speed, cost, and success rates of bringing life-changing therapies to patients. We are excited to support the continued expansion of PMG’s platform and broad therapeutic reach.”

Goldman Sachs & Co. LLC acted as lead financial advisor to PMG. Jefferies LLC and Perella Weinberg Partners also acted as financial advisors to PMG and Debevoise & Plimpton LLP acted as legal advisor to PMG. Morgan Stanley & Co. LLC, BofA Securities, and Barclays acted as financial advisors and Sullivan & Cromwell LLP acted as legal advisor to Blackstone. Terms of the transaction were not disclosed.

About Precision Medicine Group:

Formed in 2012, Precision Medicine Group is a specialized services company supporting next generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland with offices throughout North America and Europe. For more information, visit precisionmedicinegrp.com.

About Blackstone

Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $584 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.


© Business Wire 2020
All news about THE BLACKSTONE GROUP INC.
10:04aBLACKSTONE : Morgan Stanley Adjusts The Blackstone Group PT to $78 From $68, Mai..
MT
09:22aBLACKSTONE : UBS Adjusts Blackstone Group's Price Target to $70 From $62, Reiter..
MT
01/25Foley Trasimene Acquisition Company, Human Resources Provider Alight to Merge..
MT
01/25Blank Check Co. Foley Trasimene Up 6% on Deal With Alight Solutions
DJ
01/25Foley-backed SPAC agrees to $7.3 billion deal with Blackstone's Alight
RE
01/25OPTIONS : Straddle Prices for Stocks Expected to Report Quarterly Results This W..
MT
01/25MARKET CHATTER : Foley Trasimene Acquisition, Alight Solutions Reportedly Nearin..
MT
01/24SOILBUILD BUSINESS SPACE REIT : Court Sets Date to Hear Soilbuild Business Space..
MT
01/24FOLEY-BACKED SPAC NEARS $7.3 BILLION : sources
RE
01/22Blackstone-backed Patria eyes expansion in Latam, Asia
RE
More news
Financials (USD)
Sales 2020 5 924 M - -
Net income 2020 3 007 M - -
Net Debt 2020 7 077 M - -
P/E ratio 2020 26,7x
Yield 2020 3,20%
Capitalization 45 094 M 45 094 M -
EV / Sales 2020 8,81x
EV / Sales 2021 6,84x
Nbr of Employees 2 905
Free-Float 98,7%
Chart THE BLACKSTONE GROUP INC.
Duration : Period :
The Blackstone Group Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THE BLACKSTONE GROUP INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,17 $
Last Close Price 64,98 $
Spread / Highest target 23,1%
Spread / Average Target 6,44%
Spread / Lowest Target -10,7%
EPS Revisions
Managers and Directors
NameTitle
Stephen Allen Schwarzman Chairman & Chief Executive Officer
Jonathan D. Gray President, Chief Operating Officer & Director
Michael S. Chae Chief Financial Officer
John Stecher Chief Technology Officer
Hamilton Evans James Executive Vice Chairman & Director
Sector and Competitors
1st jan.Capitalization (M$)
THE BLACKSTONE GROUP INC.0.26%45 094
LEGAL & GENERAL PLC-3.76%20 764
AMUNDI-4.57%15 567
FRANKLIN RESOURCES, INC.6.08%13 411
THE CARLYLE GROUP INC.4.99%11 670
HARGREAVES LANSDOWN PLC8.72%10 727